# Why the four arms of REDEFINE 1 mattered for cagrilintide

- Article ID: research-060
- Product: Cagrilintide (cagrilintide-701)
- Canonical page: https://heritagebiolabs.com/research-library/articles/060-why-the-four-arms-of-redefine-1-mattered-for-cagrilintide
- Product collection: https://heritagebiolabs.com/research-library/products/cagrilintide
- Product page: https://heritagebiolabs.com/product/cagrilintide-701
- Reading focus: Study findings (Reading focus is a navigational tag, not an evidence grade.)
- Source years: 2025, 2026

> Educational article about published research. For research use only; not medical advice. Literature does not establish the identity, purity or activity of a purchased lot, and studies of individual components do not validate a blend.

Peptides are short chains whose amino acids are linked by peptide bonds. Some work by activating receptors that sense signals from the gut or pancreas. Cagrilintide is an investigational long-acting amylin-based peptide. The older primary REDEFINE 1 report matters for the specific question of cagrilintide alone because the large weight-management trial included a separate cagrilintide arm alongside the fixed combination. [1]

The study randomized 3,417 adults with overweight and a related complication or with obesity. They did not have diabetes. The participants were assigned to the combination of cagrilintide and semaglutide, cagrilintide alone, semaglutide alone, or placebo. Lifestyle support was part of all four groups. A four-arm design lets investigators ask how much weight changed with each assigned intervention and how the combination compares with its individual components in the same population. [1]

The main statistical tests compared the combination with placebo. At 68 weeks, the mean estimated weight change was −20.4% with the combination and −3.0% with placebo under an analysis intended to reflect treatment assignment regardless of whether participants stayed on the assigned intervention. The separate cagrilintide arm included 302 people, compared with 2,108 in the combination arm. That difference in group size matters because a group with fewer participants generally yields less precise estimates, all else being equal. It also reflects the study’s primary focus on the combination. [1]

Two outcomes were designated primary. One measured average percentage weight change and the other asked how many people reached at least a 5% reduction. An average can move substantially even when responses vary across the group. A threshold tells the reader something about how frequently people reached a specified result. Looking at both types of outcome gives a fuller account of the weight response than either measure by itself. [1]

The cagrilintide-only arm is direct human evidence about a defined preparation and population, while the 20.4% estimate belongs to the tested pair. Applying it to cagrilintide alone would assign a result to a different intervention. The older primary paper also supplies the context for later analyses of participants’ blood pressure and other measures. Those papers can extend the set of outcomes reported from REDEFINE 1. Because they use the same participants, they do not constitute independent replications of the main weight result. New monotherapy trials can add independent evidence when they report outcomes. Their registry plans identify separate placebo comparisons in people with and without type 2 diabetes. [1, 2, 3]

## Sources

1. W. Timothy Garvey et al. Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity. The New England Journal of Medicine (publication 2025-06-22). <https://pubmed.ncbi.nlm.nih.gov/40544433/>
2. Novo Nordisk A/S. Efficacy and Safety of Cagrilintide for Weight Management in Participants With Overweight or Obesity. ClinicalTrials.gov (publication 2025-10-24, record updated 2026-08-06). <https://clinicaltrials.gov/study/NCT07220642>
3. Novo Nordisk A/S. Efficacy and Safety of Cagrilintide for Weight Management in Participants With Overweight or Obesity and Type 2 Diabetes. ClinicalTrials.gov (publication 2025-10-24, record updated 2026-10-07). <https://clinicaltrials.gov/study/NCT07220759>

## Provenance

Article titles, body paragraphs and numbered citations extracted without rewriting from owner-supplied Word volumes. Product mappings use exact catalog labels; reading-focus tags and excerpts are navigational metadata. No independent peer-review or comprehensive source verification is claimed. Source volume: Peptide Research Articles 012 - Cagrilintide.docx; article 60; content SHA-256 86ec668340e38b9e1c52549811a4be932b3f2c4e53ef842df1b597c89dfbffea.
